Abstract 53P
Background
Breast cancer is the predominant malignancy in Indonesia, as per recent data from The Global Cancer Observatory (GLOBOCAN) 2020. Employing a multifaceted therapeutic approach has curbed breast cancer patient mortality. Radiotherapy's pivotal role in comprehensive breast cancer care underscores its significance. This study marks the inaugural effort to assess radiotherapy utilization rate (RUR) among Indonesian breast cancer patients.
Methods
Secondary data were gathered from breast cancer patients diagnosed within Indonesian radiotherapy centers during 2019-2021. The primary goal was a pre-pandemic evaluation of radiotherapy utilization. After rigorous data cleansing, involving duplicate elimination, meticulous analysis ensued. This unveiled actual RUR (aRUR) and optimal RUR (oRUR) for this cohort. Comparative RUR assessment with global counterparts complemented the analysis.
Results
This study encompassed 11,037 breast cancer patients from 34 Indonesian radiotherapy centers. Of these, 96.8% were female, with a minority (2.6%) being male. Notably, 60.38% were diagnosed at advanced stages (Stages 3 and 4), mirroring developing nation trends. 17 radiotherapy centers met the criteria for aRUR analysis, resulting in 26.2%. For oRUR, 9 centers were suitable, indicating 66.3% (50.7% - 78.2%). Consequently, unmet RUR needs in Indonesian breast cancer patients stood at 60.4% (48.3% - 66.4%). Data from Australia's Cancer Collaboration for Cancer Outcomes, Research & Evaluation (CCORE) 2013 exhibited a higher oRUR of 83.5% (82.5% - 84.6%), attributed to significant stage distribution differences.
Conclusions
The underutilization of radiotherapy for Indonesian breast cancer patients persists. A notable disparity between oRUR and aRUR remains. Given these outcomes, imperative next steps entail delving into underlying factors fueling this gap and devising targeted strategies to mitigate the concern.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract